High-Throughput Chaperone Screening for HGD Variants in AKU

Study Background and Research Question

Alkaptonuria (AKU) is a rare, inherited metabolic disorder characterized by a deficiency in homogentisate 1,2-dioxygenase (HGD), a hepatic enzyme crucial for tyrosine catabolism. The resulting accumulation of homogentisic acid (HGA) leads to ochronosis, progressive joint degeneration, and severe osteoarticular complications. Over 60% of pathogenic AKU mutations are missense variants that destabilize the complex hexameric HGD enzyme, causing diminished enzymatic activity and disease progression. Although nitisinone (NTBC) is approved as a disease-modifying therapy, its side effects—including hypertyrosinemia and associated complications—highlight the need for alternative, genotype-targeted treatments. The primary research question addressed by Lequeue et al. (2025) is whether pharmacological chaperones can be identified to stabilize mutant HGD proteins and restore catalytic activity, offering a new avenue for personalized AKU therapy. [source: paper]

Key Innovation from the Reference Study

The central innovation lies in the development and validation of a robust high-throughput screening (HTS) assay in Escherichia coli expressing human HGD missense variants. Unlike prior approaches limited by throughput or variant specificity, this assay enables quantitative, scalable assessment of maleylacetoacetate (MAA) formation—the direct enzymatic product—facilitating rapid identification of small molecules capable of stabilizing diverse HGD variants. The assay achieves high robustness parameters (Z′-value > 0.4, signal window > 2), supporting reproducibility and cross-variant applicability. This approach bridges the gap between genotype-phenotype correlation studies and actionable compound screening, directly addressing the personalized medicine challenge in AKU. [source: paper]

Methods and Experimental Design Insights

The authors cloned and expressed human HGD variants in E. coli, focusing on prevalent missense mutations such as HGD^G161R. The HTS assay quantifies time-dependent MAA generation from HGA substrate, providing a direct readout of residual HGD activity. Assay optimization was guided by signal-to-noise assessment and Z′-factor analysis, ensuring robust screening conditions. Importantly, the study employed a 2,320-compound FDA-approved bioactive compound library for screening, enabling drug repositioning opportunities and improving translational potential. Lead hits were further analyzed for dose-response effects and binding mechanisms via molecular docking using CB-Dock, with particular attention to stabilization of HGD prior to substrate/cofactor binding. [source: paper]

Protocol Parameters

• assay | high-throughput screening (HTS) in E. coli | missense HGD variant assessment | enables quantitative comparison across variants; scalable for library screening | paper | link
• assay readout | maleylacetoacetate (MAA) formation (time-dependent) | HGD enzymatic activity quantification | direct correlation to residual HGD function | paper | link
• compound library | 2,320 FDA/EMA/CFDA/PMDA-approved bioactive compounds | drug repositioning, pharmacological chaperone identification | ensures clinical relevance and safety profile | paper | link
• assay robustness | Z′-value > 0.4; signal window > 2 | HTS for rare missense variants | supports reproducibility and cross-lab transferability | paper | link
• hit selection cutoff | ≥3-fold activity increase over untreated variant | lead compound prioritization | balances sensitivity and specificity for pharmacological chaperone discovery | paper | link
• storage of compound solutions | 10 mM in DMSO, stable for 12-24 months at -20°C to -80°C | HTS workflow continuity | avoids compound degradation during large-scale screens | product_spec | link

Core Findings and Why They Matter

The screening identified 30 compounds that increased HGD^G161R catalytic activity by at least threefold, highlighting the feasibility of pharmacological chaperone therapy for AKU. Notably, compound 21 exhibited a clear dose-dependent effect, doubling residual activity at 100 and 250 μM. Molecular docking suggested that compound 21 binds preferentially at the active site loop and C-terminal β-sheet in the apo-HGD structure, supporting a stabilization mechanism prior to substrate and Fe²⁺ cofactor association. These findings establish the HTS assay as both a variant-ranking tool (for genotype–phenotype studies) and a platform for discovering clinically actionable chaperones. This work thus directly advances drug repositioning screening in rare metabolic disorders, providing a template for analogous efforts in other protein misfolding diseases. [source: paper]

Comparison with Existing Internal Articles

Several internal resources discuss the application of FDA-approved bioactive compound libraries in high-throughput pharmacological target identification and drug repositioning. For example, the article "DiscoveryProbe™ FDA-approved Drug Library: Enabling Next-..." outlines how large-scale compound libraries expedite both covalent and non-covalent inhibitor discovery, aligning with the present study’s approach but extending its relevance to broader disease contexts. Another resource, "Solving Cell-Based Assay Challenges with DiscoveryProbe™ ...", highlights practical workflow solutions and assay reproducibility, topics echoed by the robustness parameters achieved in the reference study. The present paper’s focus on rare metabolic disease screening broadens the translational application of these libraries, particularly in the context of genotype-specific drug discovery. Internal articles addressing neurodegenerative disease drug discovery and cancer research drug screening underscore the versatility of high-content screening compound collections for both mechanistic and therapeutic innovation.

Limitations and Transferability

While the bacterial expression system enables rapid screening, it may not fully recapitulate post-translational modifications or complex folding environments of human hepatocytes. Confirmatory assays in mammalian systems and in vivo models will be essential to validate candidate chaperones’ efficacy and safety. Additionally, the mechanistic insights obtained for compound 21 may not generalize to all identified hits, necessitating further structural and functional validation. Cross-domain transferability to other protein misfolding disorders is promising, but disease-specific biochemical and cellular contexts must be considered before broader application. [source: paper]

Research Support Resources

To enable similar high-throughput drug repositioning screening and pharmacological target identification workflows, researchers can utilize the DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021). This comprehensive library of 2,320 clinically approved bioactive compounds is optimized for both high-throughput and high-content screening applications, as highlighted in both the reference study and supporting internal resources. Its format and stability are well-suited for reproducible compound screening in metabolic, cancer, and neurodegenerative disease models [product_spec: link].